文献速递白血病

急性髓系白血病靶向治疗进展

Updates on targeted therapies for acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2021-08-04

综述总结近年来急性髓系白血病(AML)靶向治疗进展,指出细胞遗传学和分子异常是化疗反应和长期结局的最重要决定因素,且为潜在治疗靶点。二代测序促进小分子药物开发,吉妥珠单抗奥唑米星、维奈克拉、FLT3抑制剂、IDH抑制剂等已成为治疗现实,部分药物可能 soon 成为新标准。

要点

  • 细胞遗传学和分子异常是AML化疗反应和长期结局的最重要决定因素。
  • 二代测序促进AML小分子靶向药物开发,多个药物已获批。
  • 吉妥珠单抗奥唑米星、维奈克拉、FLT3抑制剂、IDH抑制剂等已成为治疗现实。

核心结论

  • AML靶向治疗领域大量阳性数据允许重新考虑年轻和老年AML患者可能的新标准治疗。

研究设计与样本

  • 综述,总结近期获批的AML疗法并讨论现在和未来的研究方向。

主要发现

  • 许多2018年AML综述中的 hopeful 预测现已成为治疗现实:吉妥珠单抗奥唑米星、维奈克拉、FLT3抑制剂(米哚妥林、吉瑞替尼)、IDH抑制剂(艾伏尼布、恩西地平)、CPX-351、格拉吉布、口服地西他滨和口服阿扎胞苷。
  • 其他药物可能 soon 成为现实:quizartinib、APR246 magrolimab、menin抑制剂。

临床怎么用

  • 基于细胞遗传学和分子异常确定AML治疗反应和长期结局,并作为潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past few years research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to remarkable advances in our understanding of the disease. Cytogenetic and molecular aberrations are the most important factors in determining response to chemotherapy as well as long-term outcome, but beyond prognostication are potential therapeutic targets. Our increased understanding of the pathogenesis of AML facilitated by next-generation sequencing has spurred the development of new compounds in the treatment of AML, particularly the creation of small molecules that target the disease on a molecular level. Many of the hopeful predictions outlined in our AML review of 2018 are now therapeutic realities: gemtuzumab ozogamicin, venetoclax, FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (ivosidenib, enasidenib), CPX-351, glasdegib, oral decitabine, and oral azacitidine. Others may soon be (quizartinib, APR246 magrolimab, menin inhibitors). The wealth of positive data allows reconsideration of what might soon be new standards of care in younger and older patients with AML. In this review we give an overview of recently approved therapies in AML and address present and future research directions.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2021. PMID: 34350585. doi:10.1111/bjh.17746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。